Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Feb 21;2(2):CD002025.
doi: 10.1002/14651858.CD002025.pub5.

Buprenorphine for managing opioid withdrawal

Linda Gowing  1 , Robert Ali  1 , Jason M White  2 , Dalitso Mbewe  1
Affiliations
Meta-Analysis

Buprenorphine for managing opioid withdrawal

Linda Gowing et al. Cochrane Database Syst Rev. .

Abstract

Background: Managed withdrawal is a necessary step prior to drug-free treatment or as the endpoint of substitution treatment.

Objectives: To assess the effects of buprenorphine versus tapered doses of methadone, alpha2-adrenergic agonists, symptomatic medications or placebo, or different buprenorphine regimens for managing opioid withdrawal, in terms of the intensity of the withdrawal syndrome experienced, duration and completion of treatment, and adverse effects.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 11, 2016), MEDLINE (1946 to December week 1, 2016), Embase (to 22 December 2016), PsycINFO (1806 to December week 3, 2016), and the Web of Science (to 22 December 2016) and handsearched the reference lists of articles.

Selection criteria: Randomised controlled trials of interventions using buprenorphine to modify the signs and symptoms of withdrawal in participants who were primarily opioid dependent. Comparison interventions involved reducing doses of methadone, alpha2-adrenergic agonists (clonidine or lofexidine), symptomatic medications or placebo, and different buprenorphine-based regimens.

Data collection and analysis: We used standard methodological procedures expected by Cochrane.

Main results: We included 27 studies involving 3048 participants. The main comparators were clonidine or lofexidine (14 studies). Six studies compared buprenorphine versus methadone, and seven compared different rates of buprenorphine dose reduction. We assessed 12 studies as being at high risk of bias in at least one of seven domains of methodological quality. Six of these studies compared buprenorphine with clonidine or lofexidine and two with methadone; the other four studies compared different rates of buprenorphine dose reduction.For the comparison of buprenorphine and methadone in tapered doses, meta-analysis was not possible for the outcomes of intensity of withdrawal or adverse effects. However, information reported by the individual studies was suggestive of buprenorphine and methadone having similar capacity to ameliorate opioid withdrawal, without clinically significant adverse effects. The meta-analyses that were possible support a conclusion of no difference between buprenorphine and methadone in terms of average treatment duration (mean difference (MD) 1.30 days, 95% confidence interval (CI) -8.11 to 10.72; N = 82; studies = 2; low quality) or treatment completion rates (risk ratio (RR) 1.04, 95% CI 0.91 to 1.20; N = 457; studies = 5; moderate quality).Relative to clonidine or lofexidine, buprenorphine was associated with a lower average withdrawal score (indicating less severe withdrawal) during the treatment episode, with an effect size that is considered to be small to moderate (standardised mean difference (SMD) -0.43, 95% CI -0.58 to -0.28; N = 902; studies = 7; moderate quality). Patients receiving buprenorphine stayed in treatment for longer, with an effect size that is considered to be large (SMD 0.92, 95% CI 0.57 to 1.27; N = 558; studies = 5; moderate quality) and were more likely to complete withdrawal treatment (RR 1.59, 95% CI 1.23 to 2.06; N = 1264; studies = 12; moderate quality). At the same time there was no significant difference in the incidence of adverse effects, but dropout due to adverse effects may be more likely with clonidine (RR 0.20, 95% CI 0.04 to 1.15; N = 134; studies = 3; low quality). The difference in treatment completion rates translates to a number needed to treat for an additional beneficial outcome of 4 (95% CI 3 to 6), indicating that for every four people treated with buprenorphine, we can expect that one additional person will complete treatment than with clonidine or lofexidine.For studies comparing different rates of reduction of the buprenorphine dose, meta-analysis was possible only for treatment completion, with separate analyses for inpatient and outpatient settings. The results were diverse, and we assessed the quality of evidence as being very low. It remains very uncertain what effect the rate of dose taper has on treatment outcome.

Authors' conclusions: Buprenorphine is more effective than clonidine or lofexidine for managing opioid withdrawal in terms of severity of withdrawal, duration of withdrawal treatment, and the likelihood of treatment completion.Buprenorphine and methadone appear to be equally effective, but data are limited. It remains possible that the pattern of withdrawal experienced may differ and that withdrawal symptoms may resolve more quickly with buprenorphine.It is not possible to draw any conclusions from the available evidence on the relative effectiveness of different rates of tapering the buprenorphine dose. The divergent findings of studies included in this review suggest that there may be multiple factors affecting the response to the rate of dose taper. One such factor could be whether or not the initial treatment plan includes a transition to subsequent relapse prevention treatment with naltrexone. Indeed, the use of buprenorphine to support transition to naltrexone treatment is an aspect worthy of further research.Most participants in the studies included in this review were male. None of the studies reported outcomes on the basis of sex, preventing any exploration of differences related to this variable. Consideration of sex as a factor influencing response to withdrawal treatment would be relevant research for selecting the most appropriate type of intervention for each individual.

PubMed Disclaimer

Conflict of interest statement

Linda Gowing: none known.

Robert Ali: none known.

Jason M White: none known.

Dalitso Mbewe: none known.

Figures

1
1
Study flow diagram.
2
2
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
3
3
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
1.1
1.1. Analysis
Comparison 1 Buprenorphine versus methadone, Outcome 1 Mean days in treatment.
1.2
1.2. Analysis
Comparison 1 Buprenorphine versus methadone, Outcome 2 Completion of withdrawal treatment.
2.1
2.1. Analysis
Comparison 2 Buprenorphine versus clonidine, Outcome 1 Mean peak withdrawal score.
2.2
2.2. Analysis
Comparison 2 Buprenorphine versus clonidine, Outcome 2 Mean overall withdrawal score.
2.3
2.3. Analysis
Comparison 2 Buprenorphine versus clonidine, Outcome 3 Mean days in treatment.
2.4
2.4. Analysis
Comparison 2 Buprenorphine versus clonidine, Outcome 4 Number experiencing adverse effects.
2.5
2.5. Analysis
Comparison 2 Buprenorphine versus clonidine, Outcome 5 Number with treatment stopped due to adverse effects.
2.6
2.6. Analysis
Comparison 2 Buprenorphine versus clonidine, Outcome 6 Number completing withdrawal treatment.
3.1
3.1. Analysis
Comparison 3 Rapid versus slow dose taper, Outcome 1 Completion of withdrawal treatment.
3.2
3.2. Analysis
Comparison 3 Rapid versus slow dose taper, Outcome 2 Number abstinent at completion of dose taper.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Amass 1994 {published data only}
    1. Amass L, Bickel WK, Higgins ST, Hughes JR. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. Journal of Addictive Diseases 1994;13(3):33‐45. [MEDLINE: ] - PubMed
Assadi 2004 {published data only}
    1. Assadi SM, Hafezi M, Mokri A, Razzaghi EM, Ghaeli P. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomised, double‐blind, controlled clinical trial. Journal of Substance Abuse Treatment 2004;27(1):75‐82. - PubMed
Bickel 1988 {published data only}
    1. Bickel WK, Johnson RE, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR. A clinical trial of buprenorphine: I. Comparison with methadone in the detoxification of heroin addicts. II. Examination of its opioid blocking properties. NIDA Research Monograph 1987;76:182‐8. - PubMed
    1. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clinical Pharmacology & Therapeutics 1988;43(1):72‐8. [MEDLINE: ] - PubMed
Cheskin 1994 {published and unpublished data}
    1. Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug and Alcohol Dependence 1994;36(2):115‐21. [MEDLINE: ] - PubMed
Collins 2005 {published data only}
    1. Collins ED, Kleber HD, Whittington RA, Heitler NE. Anesthesia‐assisted vs buprenorphine‐ or clonidine‐assisted heroin detoxification and naltrexone induction. A randomised trial. JAMA 2005;294(8):903‐13. - PubMed
    1. Collins ED, Whittington RA, Heitler NE, Kleber HD. A randomised comparison of anaesthesia‐assisted heroin detoxification with buprenorphine‐ and clonidine‐assisted detoxifications. Drug and Alcohol Dependence 2002;66(Suppl):S35.
Hopper 2005 {published data only}
    1. Hopper JA, Wu J, Martus W, Pierre JD. A randomized trial of one‐day vs. three‐day buprenorphine inpatient detoxification protocols for heroin dependence. Journal of Opioid Management 2005;1(1):31‐5. - PubMed
Hussain 2015 {published data only}
    1. Hussain SS, Farhat S, Rather YH, Abbas Z. Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine‐naloxone in opioid withdrawal: a hospital based study. Journal of Clinical and Diagnostic Research 2015;9(1):FC01‐FC4. - PMC - PubMed
Janiri 1994 {published data only}
    1. Janiri L, Mannelli P, Persico AM, Serretti A, Tempesta E. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug and Alcohol Dependence 1994;36(2):139‐45. [MEDLINE: ] - PubMed
    1. Janiri L, Mannelli P, Serretti A, Tempesta E. Low‐dose buprenorphine detoxification in long term methadone addicts. Regulatory Peptides 1994;Suppl(1):289‐90.
Ling 2005 {published data only}
    1. Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, et al. Bringing buprenorphine‐naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network Field Experience. American Journal on Addictions 2004;13(Suppl):S42‐66. - PMC - PubMed
    1. Hillhouse M, Domier CP, Chim D, Ling W. Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomes. Journal of Addictive Diseases 2010;29(1):23‐9. - PMC - PubMed
    1. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, et al. A multi‐centre randomised trial of buprenorphine‐naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005;100(8):1090‐100. - PMC - PubMed
    1. Ziedonis DM, Amass L, Steinberg M, Woody G, Krejci J, Annon JJ, et al. Predictors of outcome for short‐term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine‐naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. Drug and Alcohol Dependence 2009;99(1‐3):28‐36. - PMC - PubMed
Ling 2009 {published data only}
    1. Brown ES, Tirado C, Minhajuddin A, Hillhouse M, Adinoff B, Ling W, et al. Association of race and ethnicity with withdrawal symptoms, attrition, opioid use, and side‐effects during buprenorphine therapy. Journal of Ethnicity in Substance Abuse 2010;9(2):106‐14. - PMC - PubMed
    1. Hillhouse M, Canamar CP, Doraimani G, Thomas C, Hasson A, Ling W. Participant characteristics and buprenorphine dose. American Journal of Drug and Alcohol Abuse 2011;37(5):453‐9. - PMC - PubMed
    1. Hillhouse M, Canamar CP, Ling W. Predictors of outcome after short‐term stabilization with buprenorphine. Journal of Substance Abuse Treatment 2013;44(3):336‐42. - PMC - PubMed
    1. Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009;104(2):256‐65. - PMC - PubMed
    1. Nielsen S, Hillhouse M, Thomas C, Hasson A, Ling W. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. Journal of Addiction Medicine 2013;7(1):33‐8. - PMC - PubMed
Lintzeris 2002 {published data only}
    1. Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L. A randomised controlled trial of buprenorphine in the management of short‐term ambulatory heroin withdrawal. Addiction 2002;97(11):1395‐404. - PubMed
Marsch 2005 {published data only}
    1. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al. Comparison of pharmacological treatments for opioid‐dependent adolescents: a randomized controlled trial. Archives of General Psychiatry 2005;62(10):1157‐64. - PubMed
    1. Moore SK, Marsch LA, Badger GJ, Solhkhah R, Hofstein Y. Improvement in psychopathology among opioid‐dependent adolescents during behavioral‐pharmacological treatment. Journal of Addiction Medicine 2011;5(4):264‐71. - PMC - PubMed
    1. Motamed M, Marsch LA, Solhkhah R, Bickel WK, Badger GJ. Differences in treatment outcomes between prescription opioid‐dependent and heroin‐dependent adolescents. Journal of Addiction Medicine 2008;2(3):158‐64. - PubMed
Marsch 2016 {published data only}
    1. Marsch LA, Moore SK, Borodovsky JT, Solhkhah R, Badger GJ, et al. A randomized controlled trial of buprenorphine taper duration among opioid‐dependent adolescents and young adults. Addiction 2016;111(8):1406‐15. [DOI: ] - PMC - PubMed
Nigam 1993 {published and unpublished data}
    1. Nigam AK, Ray R, Tripathi BM. Buprenorphine in opiate withdrawal: a comparison with clonidine. Journal of Substance Abuse Treatment 1993;10(4):391‐4. [MEDLINE: ] - PubMed
O'Connor 1997 {published data only}
    1. O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomized trial. Annals of Internal Medicine 1997;127(7):526‐30. [MEDLINE: ] - PubMed
    1. Shi JM, O'Connor PG, Constantino JA, Carroll KM, Schottenfeld RS, Rounsaville BJ. Three methods of ambulatory opiate detoxification: preliminary results of a randomised clinical trial. NIDA Research Monograph 1993;132:309.
Oreskovich 2005 {published data only}
    1. Oreskovich MR, Saxon AJ, Ellis ML, Malte CA, Reoux JP, Knox PC. A double‐blind, double‐dummy, randomized, prospective pilot study of the partial Mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug and Alcohol Dependence 2005;77(1):71‐9. [Embase 2004536231] - PubMed
Petitjean 2002 {published and unpublished data}
    1. Petitjean S, Bardeleben U, Weber M, Ladewig D. Buprenorphine versus methadone in opiate detoxification: preliminary results. Drug and Alcohol Dependence 2002;66(Suppl):S138.
Ponizovsky 2006 {published data only}
    1. Ponizovsky AM, Grinshpoon A, Margolis A, Cohen R, Rosca P. Well‐being, psychosocial factors, and side‐effects among heroin‐dependent inpatients after detoxification using buprenorphine versus clonidine. Addictive Behaviors 2006;31(11):2002‐13. - PubMed
Raistrick 2005 {published data only}
    1. Raistrick D, West D, Finnegan O, Thistlewaite G, Brearley R, Banbery J. A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial. Addiction 2005;100(12):1860‐7. - PubMed
Schneider 2000 {published data only}
    1. Paetzold W, Eronat V, Seifert J, Holze I, Emrich HM, Schneider U. Detoxification of poly‐substance abusers with buprenorphine. Effects on affect, anxiety, and withdrawal symptoms [Detoxifikation polytoxikomaner Patienten mit Buprenorphin. Auswirkungen auf Affektivitat, Angst und Entzugssymptomaik]. Nervenarzt 2000;71(9):722‐9. [MEDLINE: ] - PubMed
    1. Schneider U, Paetzold W, Eronat V, Huber TJ, Seifert J, Wiese B, et al. Buprenorphine and carbamazepine as a treatment for detoxification of opiate addicts with multiple drug misuse: a pilot study. Addiction Biology 2000;5:65‐9. - PubMed
Seifert 2002 {published data only}
    1. Seifert J, Metzner C, Paetzold W, Borsutzky M, Ohlmeier M, Passie T, et al. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone. Addiction Biology 2005;10(2):157‐64. - PubMed
    1. Seifert J, Metzner C, Paetzold W, Borsutzky M, Passie T, Rollnik J, et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry 2002;35(5):159‐64. [MEDLINE: ] - PubMed
Sigmon 2013 {published data only}
    1. Dunn KE, Saulsgiver KA, Miller ME, Nuzzo PA, Sigmon SC. Characterizing opioid withdrawal during double‐blind buprenorphine detoxification. Drug and Alcohol Dependence 2015;151:47‐55. [DOI: 10.1016/j.drugalcdep.2015.02.033] - DOI - PMC - PubMed
    1. Patrick ME, Dunn KE, Badger GJ, Heil SH, Higgins ST, Sigmon SC. Spontaneous reductions in smoking during double‐blind buprenorphine detoxification. Addictive Behaviors 2014;39(9):1353‐6. - PMC - PubMed
    1. Sigmon SC, Dunn KE, Saulsgiver K, Patrick ME, Badger GJ, Heil SH, et al. A randomized, double‐blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 2013;70(12):1347‐54. - PMC - PubMed
Steinmann 2008 {published data only}
    1. Steinmann C, Artmann S, Henneberg B, Paul HW. Should methadone or buprenorphine be preferred for opiate detoxification? [Methadon‐racemat versus buprenorphin zur stationaren entgiftungsbehandlung opiatabhangiger]. Psychiatrische Praxis 2007;34(1):S103‐5.
    1. Steinmann C, Artmann S, Schachtschneider A, Paul HW. Methadone versus buprenorphine for inpatient detoxification treatment [Methadon‐Racemat versus Buprenorphin zur stationaren Entgiftungsbehandlung]. Sucht 2008;54(4):217‐21.
Umbricht 2003 {published data only}
    1. Umbricht A, Hoover DR, Tucker MJ, Leslie JM, Chaisson RE, Preston KL. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin‐dependent patients with HIV infection. Drug and Alcohol Dependence 2003;69(3):263‐72. - PubMed
Wang 1996 {published data only}
    1. Wang RI, Young LD. Double‐blind controlled detoxification from buprenorphine. NIDA Research Monograph 1996;162:114.
Wright 2011 {published data only}
    1. Sheard L, Wright NMJ, Adams CE, Bound N, Rushforth B, Hart R, et al. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) Prisons Project Study: protocol for a randomised controlled trial comparing methadone and buprenorphine for opiate detoxification. Trials 2009;10:53. - PMC - PubMed
    1. Wright NMJ, Sheard L, Adams CE, Rushforth BJ, Harrison W, Bound N, et al. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. British Journal of General Practice 2011;61(593):e772‐80. - PMC - PubMed
Ziaaddini 2012 {published data only}
    1. Ziaaddini H, Nasirian M, Nakhaee N. A comparison of the efficacy of buprenorphine and clonidine in detoxification of heroin‐dependents and the following maintenance treatment. Addiction and Health 2010;2(1‐2):18‐24. - PMC - PubMed
    1. Ziaaddini H, Nasirian M, Nakhaee N. Comparison of the efficacy of buprenorphine and clonidine in detoxification of opioid‐dependents. Addiction and Health 2012;4(3‐4):79‐86. - PMC - PubMed

References to studies excluded from this review

Blondell 2008 {published data only}
    1. Blondell RD, Frydrych L, Arber BC, Bashaw HL, Vexler A, Purdy CH, et al. A randomized trial of extended buprenorphine detoxification for opioid dependency. Journal of Addiction Medicine 2008;2(3):139‐46. - PubMed
Breen 2003 {published data only}
    1. Breen CL, Harris SJ, Lintzeris N, Mattick RP, Hawken L, Bell J, et al. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug and Alcohol Dependence 2003;71(1):49‐55. - PubMed
Fiellin 2014 {published data only}
    1. Fiellin D, Cutter CJ, Moore BA, Barry D, O'Connor P, Schottenfeld RS. Primary care buprenorphine detoxification vs. maintenance for prescription opioid dependence. Drug and Alcohol Dependence 2015;146(12):e277.
    1. Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG. Primary care‐based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Internal Medicine 2014;174(12):1947‐54. - PMC - PubMed
Fingerhood 2001 {published data only}
    1. Fingerhood MI, Thompson MR, Jasinski DR. A comparison of clonidine and buprenorphine in the outpatient treatment of opiate withdrawal. Substance Abuse 2001;22(3):193‐9. - PubMed
Frownfelter 2001 {published data only}
    1. Frownfelter J, Hopper JA. Rapid opioid detoxification using buprenorphine and naltrexone. Drug and Alcohol Dependence 2001;63(Suppl 1):S50.
Gandhi 2003 {published data only}
    1. Gandhi DH, Jaffe JH, McNary S, Kavanagh GJ, Hayes M, Currens M. Short‐term outcomes after brief ambulatory opioid detoxification with buprenorphine in young heroin users. Addiction 2003;98(4):453‐62. [MEDLINE: ] - PubMed
Gibson 2003 {published data only}
    1. Doran CM, Shanahan M, Bell J, Gibson A. A cost‐effectiveness analysis of buprenorphine‐assisted heroin withdrawal. Drug and Alcohol Review 2004;23(2):171‐5. - PubMed
    1. Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: A randomised trial. Medical Journal of Australia 2003;179(1):38‐42. - PubMed
Gonzalez 2015 {published data only}
    1. Gonzalez G, DiGirolamo G, Kolodziej ME, Smelson D, Romero‐Gonzalez M. Memantine improves buprenorphine treatment for opioid‐dependent young adults. Drug and Alcohol Dependence 2015;146:e124. - PMC - PubMed
    1. Gonzalez G, DiGirolamo G, Kolodziej ME, Smelson D, Romero‐Gonzalez M. Memantine improves buprenorphine treatment for opioid‐dependent young adults. Drug and Alcohol Dependence 2015;156:243‐253. - PMC - PubMed
Hao 2000 {published data only}
    1. Hao W, Zhao M. A comparative clinical study of the effect of WeiniCom, a Chinese herbal compound, on alleviation of withdrawal symptoms and craving for heroin in detoxification treatment. Journal of Psychoactive Drugs 2000;32(3):277‐84. [MEDLINE: ] - PubMed
Harris 2003 {published data only}
    1. Harris L. A comparison of buprenorphine with lofexidine in the rapid opiate detoxification of patients with opiate dependency receiving treatment in a community setting. Addiction Biology 2003;8:243.
He 1999 {published data only}
    1. He M, Zhang H, Tang J, Tang Z, Yang D, Chen X, et al. A comparative study of buprenorphine plus naloxone vs opium tincture in the detoxification treatment of heroin dependence. Chinese Journal of Clinical Psychology 1999;4(1):10‐5.
Jain 2011 {published data only}
    1. Jain K, Jain R, Dhawan A. A double‐blind, double‐dummy, randomized controlled study of memantine versus buprenorphine in naloxone‐precipitated acute withdrawal in heroin addicts. Journal of Opioid Management 2011;7(1):11‐20. - PubMed
Jia 2001 {published data only}
    1. Jia Y. Effect of methadone plus buprenorphine on the alleviation of heroin withdrawal symptoms. Chinese Journal of Clinical Psychology 2001;9(1):60‐2.
Johnson 1989 {published data only}
    1. Johnson RE, Fudala PJ, Collins CC, Jaffe JH. Outpatient maintenance/detoxification comparison of methadone and buprenorphine. NIDA Research Monograph 1989;95:384. [MEDLINE: ] - PubMed
Johnson 1992a {published data only}
    1. Johnson RE, Fudala PJ, Cheskin LR. A comparison of buprenorphine to clonidine for rapid inpatient opiate detoxification. Clinical Pharmacology & Therapeutics 1992;51(2):167.
Johnson 1992b {published data only}
    1. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267(20):2750‐5. - PubMed
Johnson 1996 {published data only}
    1. Johnson RE, Eissenberg T, Alim TN, Lindquist T, Vocci FJ, Risher‐Flowers DL, et al. Comparison of the withdrawal syndromes following abrupt termination of buprenorphine and methadone. NIDA Research Monograph 1996;162:200.
Katz 2009 {published data only}
    1. Katz EC, Schwartz RP, King S, Highfield DA, O'Grady KE, Billings T, et al. Brief vs extended buprenorphine detoxification in a community treatment program: engagement and short‐term outcomes. American Journal of Drug and Alcohol Abuse 2009;35(2):63‐7. - PMC - PubMed
Kosten 1988 {published data only}
    1. Kosten TR, Kleber HD. Buprenorphine detoxification from opioid dependence: a pilot study. Life Sciences 1988;42(6):635‐41. [MEDLINE: ] - PubMed
Kosten 1991 {published data only}
    1. Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD. Opioid antagonist challenges in buprenorphine maintained patients. Drug and Alcohol Dependence 1990;25(1):73‐8. [MEDLINE: ] - PubMed
    1. Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD. Rapid detoxification from opioid dependence. American Journal of Psychiatry 1989;146(10):1349. [MEDLINE: ] - PubMed
    1. Kosten TR, Morgan C, Kleber HD. Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone. NIDA Research Monograph 1992;121:101‐19. [MEDLINE: ] - PubMed
    1. Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. American Journal of Drug and Alcohol Abuse 1991;17(2):119‐28. [MEDLINE: ] - PubMed
Law 2002 {published data only}
    1. Law FD, Myles JS, Nutt DJ. BD RCT of Suboxone (buprenorphine/naloxone) vs. methadone/lofexidine for stabilization and withdrawal of low‐dose outpatient opiate addicts. Drug and Alcohol Dependence 2002;66(Suppl 1):S100.
    1. Myles J, Law F, Raybould T. A double‐blind randomised controlled trial of buprenorphine/naloxone (suboxone) versus methadone/lofexidine for the detoxification of opiate‐dependent addicts. Drug and Alcohol Dependence 2000;60(Suppl 1):S156.
Liebschutz 2014 {published data only}
    1. Cushman PA, Anderson BJ, Moreau M, Stein MD, Liebschutz JM. Buprenorphine initiation and linkage to outpatient buprenorphine treatment does not reduce frequency of injection drug use for inpatient opioid‐dependent injection drug users: results of a randomized clinical trial. Journal of General Internal Medicine 2015;30:S114‐S5.
    1. Liebschutz J, Crooks D, Herman D, Anderson B, Meshesha L, Dossabhoy S, et al. Initiating buprenorphine maintenance for opiate‐dependent hospitalized patients: a randomized controlled trial. Journal of General Internal Medicine 2013;28:S108‐9.
    1. Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, et al. Buprenorphine treatment for hospitalized, opioid‐dependent patients: a randomized clinical trial. JAMA Internal Medicine 2014;174(8):1369‐76. - PMC - PubMed
Lintzeris 2003 {published data only}
    1. Lintzeris N, Bammer G, Rushworth L, Jolley DJ, Whelan G. Buprenorphine dosing regime for inpatient heroin withdrawal: a symptom‐triggered dose titration study. Drug and Alcohol Dependence 2003;70(3):287‐94. - PubMed
Liu 1997 {published data only}
    1. Liu ZM, Cai ZJ, Wang XP, Ge Y, Li CM. Rapid detoxification of heroin dependence by buprenorphine. Acta Pharmacologica Sinica 1997;18(2):112‐4. - PubMed
Maayan 2008 {published data only}
    1. Maayan R, Touati‐Werner D, Shamir D, Yadid G, Friedman A, Eisner D, et al. The effect of DHEA complementary treatment on heroin addicts participating in a rehabilitation program: a preliminary study. European Neuropsychopharmacology 2008;18(6):406‐13. - PubMed
Meade 2010 {published data only}
    1. Meade CS, Lukas SE, McDonald LJ, Fitzmaurice GM, Eldridge JA, Merrill N, et al. A randomized trial of transcutaneous electric acupoint stimulation as adjunctive treatment for opioid detoxification. Journal of Substance Abuse Treatment 2010;38(1):12‐21. - PMC - PubMed
Montoya 1994 {published data only}
    1. Montoya ID, Mann DJ, Ellison PA, Lange WR, Preston KL. Inpatient medically supervised opioid withdrawal, with buprenorphine alone and in combination with naltrexone. Clinical Pharmacology and Therapeutics 1994;55(2):131.
Pjrek 2012 {published data only}
    1. Pjrek E, Frey R, Naderi‐Heiden A, Strnad A, Kowarik A, Kasper S, et al. Actigraphic measurements in opioid detoxification with methadone or buprenorphine. Journal of Clinical Psychopharmacology 2012;32(1):75‐82. - PubMed
Pycha 1994 {published and unpublished data}
    1. Pycha C, Resnick RB, Galanter M. Buprenorphine: rapid and slow dose‐reductions for heroin detoxification. NIDA Research Monograph 1994;141:453.
Reed 2007 {published data only}
    1. Reed LJ, Glasper A, Wet CJ, Bearn J, Gossop M. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate‐benzodiazepine codependent patients?. Journal of Clinical Psychopharmacology 2007;27(2):188‐92. - PubMed
Resnick 1992 {published data only}
    1. Resnick RB, Galanter M, Pycha C, Cohen A, Grandison P, Flood N. Buprenorphine: an alternative to methadone for heroin dependence treatment. Psychopharmacology Bulletin 1992;28(1):109‐13. [MEDLINE: ] - PubMed
Rosen 1995 {published data only}
    1. Rosen M, Kosten TR. Detoxification and induction onto naltrexone. In: Cowan A, Lewis JW editor(s). Buprenorphine: Combatting Drug Abuse with a Unique Opioid. New York: Wiley‐Liss, 1995.
Rosenthal 2013 {published data only}
    1. Rosenthal RN, Ling W, Casadonte P, Vocci F, Bailey GL, Kampman K, et al. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. Addiction 2013;108(12):2141‐9. - PMC - PubMed
Sanders 2013 {published data only}
    1. Sanders NC, Mancino MJ, Gentry WB, Guise JB, Bickel WK, Thostenson J, et al. Randomized, placebo‐controlled pilot trial of gabapentin during an outpatient, buprenorphine‐assisted detoxification procedure. Experimental and Clinical Psychopharmacology 2013;21(4):294‐302. - PMC - PubMed
Sheard 2009 {published data only}
    1. Sheard L, Adams CE, Wright NMJ, El‐Sayeh H, Dalton R, Tompkins CNE. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project pilot study: protocol for a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification. Trials 2007;8:1. - PMC - PubMed
    1. Sheard L, Wright NMJ, El‐Sayeh HG, Adams CE, Li R, Tompkins CNE. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification. Substance Abuse Treatment, Prevention, and Policy 2009;4:1. - PMC - PubMed
Sigmon 2004 {published data only}
    1. Sigmon SC, Wong CJ, Chausmer AL, Liebson IA, Bigelow GE. Evaluation of an injection depot formulation of buprenorphine: placebo comparison. Addiction 2004;99(11):1439‐49. - PubMed
Sullivan 2015 {published data only}
    1. Sullivan MA, Bisaga A, Carpenter K, Mariani JJ, Mishlen K, Nunes EV. Long‐acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone vs buprenorphine. Drug and Alcohol Dependence 2015;146:e112. - PMC - PubMed
Tompkins 2014 {published data only}
    1. Tompkins D, Smith MT, Mintzer MZ, Campbell CM, Strain EC. A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. Journal of Pharmacology and Experimental Therapeutics 2014;348(2):217‐26. - PMC - PubMed
Umbricht 1999 {published data only}
    1. Umbricht A, Montoya ID, Hoover DR, Demuth KL, Chiang CT, Preston KL. Naltrexone shortened opioid detoxification with buprenorphine. Drug and Alcohol Dependence 1999;56(3):181‐90. - PubMed
Weiss 2010 {published data only}
    1. Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, et al. Adjunctive counseling during brief and extended buprenorphine‐naloxone treatment for prescription opioid dependence: a 2‐phase randomized controlled trial. Archives of General Psychiatry 2011;68(12):1238‐46. - PMC - PubMed
    1. Weiss RD, Potter JS, Provost SE, Huang Z, Jacobs P, Hasson A, et al. A multi‐site, two‐phase, Prescription Opioid Addiction Treatment Study (POATS): Rationale, design, and methodology. Contemporary Clinical Trials 2010;31(2):189‐99. - PMC - PubMed
White 2001 {published data only}
    1. White R, Alcorn R, Feinmann C. Two methods of community detoxification from opiates: an open‐label comparison of lofexidine and buprenorphine. Drug and Alcohol Dependence 2001;65(1):77‐83. [MEDLINE: ] - PubMed
Williams 2002 {published data only}
    1. Williams H, Remedios A, Oyefeso A, Bennett J. Buprenorphine detoxification treatment for heroin dependence: a preliminary experience in an outpatient setting. Irish Journal of Psychological Medicine 2002;19(3):80‐3. - PubMed
Woody 2008 {published data only}
    1. Hill KP, Bennett HE, Griffin ML, Connery HS, Fitzmaurice GM, Subramaniam G, et al. Association of cannabis use with opioid outcomes among opioid‐dependent youth. Drug and Alcohol Dependence 2013;132(1‐2):342‐5. - PMC - PubMed
    1. Meade CS, Weiss RD, Fitzmaurice GM, Poole SA, Subramaniam GA, Patkar AA, et al. HIV risk behavior in treatment‐seeking opioid‐dependent youth: results from a NIDA clinical trials network multisite study. Journal of Acquired Immune Deficiency Syndromes 2010;55(1):65‐72. - PMC - PubMed
    1. Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE. Cost‐effectiveness of extended buprenorphine‐naloxone treatment for opioid‐dependent youth: data from a randomized trial. Addiction 2010;105(9):1616‐24. - PMC - PubMed
    1. Subramaniam GA, Warden D, Minhajuddin A, Fishman MJ, Stitzer ML, Adinoff B, et al. Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid‐dependent youth. Journal of the American Academy of Child and Adolescent Psychiatry 2011;50(11):1120‐8. - PMC - PubMed
    1. Warden D, Subramaniam GA, Carmody T, Woody GE, Minhajuddin A, Poole SA, et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addictive Behaviors 2012;37(9):1046‐53. - PMC - PubMed
Wright 2007 {published data only}
    1. Oldham NS, Wright NM, Adams CE, Sheard L, Tompkins CN. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) project: an open‐label pragmatic randomised control trial comparing the efficacy of differing therapeutic agents for primary care detoxification from either street heroin or methadone [ISRCTN07752728]. BMC Family Practice 2004;5(1):9. - PMC - PubMed
    1. Wright NM, Sheard L, Tompkins CN, Adams CE, Allgar VL, Oldham NS. Buprenorphine versus dihydrocodeine for opiate detoxification in primary care: a randomised controlled trial. BMC Family Practice 2007;8:3. - PMC - PubMed
Zhang 1993 {published data only}
    1. Zhang R, Li J, Wan W. Comparative study of buprenorphine and methadone in the treatment of heroin addicts. Chinese Journal of Neurological and Mental Diseases 1993;19(5):295‐96.

Additional references

Amato 2011
    1. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD005031.pub2] - DOI - PubMed
Amato 2013
    1. Amato L, Davoli M, Ferri M, Ali R. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD003409.pub4] - DOI - PubMed
Ang‐Lee 2006
    1. Ang‐Lee K, Oreskovich MR, Saxon AJ, Jaffe C, Meredith C, Ellis ML, et al. Single dose of 24 milligrams of buprenorphine for heroin detoxification: an open‐label study of five inpatients. Journal of Psychoactive Drugs 2006;38(4):505‐12. - PubMed
Atkins 2004
    1. Atkins D, Best D, Briss PA, Eccles M, Falck‐Ytter Y, Flottorp S, et al. GRADE working group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490‐4. - PMC - PubMed
Banys 1994
    1. Banys P, Clark HW, Tusel DJ, Sees K, Stewart P, Mongan L, et al. An open trial of low dose buprenorphine in treating methadone withdrawal. Journal of Substance Abuse Treatment 1994;11(1):9‐15. [MEDLINE: ] - PubMed
Broers 2000
    1. Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva: follow‐up at 1 and 6 months. Drug and Alcohol Dependence 2000;58(1):85‐92. - PubMed
Cameron 2001
    1. Cameron D, Allen D, Galway K. A pilot study of the effectiveness of buprenorphine and methadone as detoxication agents when choice is given to the consumer. Journal of Substance Use 2001;6(2):101‐9.
Chawarski 2005
    1. Chawarski MC, Moody DE, Pakes J, O'Connor PG, Schottenfeld RS. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy and symptoms. Journal of Substance Abuse Treatment 2005;29:307‐12. - PubMed
Chiang 2003
    1. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug and Alcohol Dependence 2003;70(Suppl):S39‐S47. - PubMed
Day 2005
    1. Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD004580.pub2] - DOI - PubMed
Elkader 2005
    1. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clinical Pharmacokinetics 2005;44(7):661‐80. - PubMed
Farrell 1994
    1. Farrell M. Opiate withdrawal. Addiction 1994;89(11):1471‐5. - PubMed
Gossop 1988
    1. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug and Alcohol Dependence 1988;21(3):253‐9. - PubMed
Gossop 1989a
    1. Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow‐up study. British Journal of Psychiatry 1989;154:348‐53. - PubMed
Gossop 1989b
    1. Gossop M, Griffiths P, Bradley B, Strang J. Opiate withdrawal symptoms in response to 10 day and 21 day methadone withdrawal programmes. British Journal of Psychiatry 1989;154:360‐3. [MEDLINE: ] - PubMed
Gowing 2009
    1. Gowing L, Ali R, White J. Opioid antagonists with minimal sedation for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD002021.pub3] - DOI - PubMed
Gowing 2010
    1. Gowing LR, Ali RL, White JM. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD002022.pub3] - DOI - PMC - PubMed
Gowing 2014
    1. Gowing L, Ali R, Dunlop A, Farrell M, Lintzeris N. National Guidelines for Medication‐Assisted Treatment of Opioid Dependence. Commonwealth of Australia, 2014. www.nationaldrugstrategy.gov.au/internet/drugstrategy/Publishing.nsf/con... accessed prior to 18 January 2017. [Online ISBN: 978‐1‐74241‐945‐9]
Gowing 2015
    1. Gowing LR, Ali RL, Allsop S, Marsden J, Turf EE, West R, et al. Global statistics on addictive behaviours: 2014 status report. Addiction 2015;110(6):904‐19. [DOI: 10.1111/add.12899] - DOI - PubMed
Gowing 2016
    1. Gowing LR, Farrell M, Ali RL, White JM. Alpha2‐adrenergic agonists for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2016, Issue 5. [DOI: 10.1002/14651858.CD002024.pub5] - DOI - PMC - PubMed
GRADEpro GDT [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed prior to 17 January 2017. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Guyatt 2008a
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al GRADE working group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7560):924‐6. - PMC - PubMed
Guyatt 2008b
    1. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck‐Ytter Y, Schünemann HJ, GRADE Working Group. Rating quality of evidence and strength of recommendations: What is "quality of evidence" and why is it important to clinicians?. BMJ 2008;336(7651):955‐8. - PMC - PubMed
Guyatt 2011
    1. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al GRADE working group. GRADE guidelines 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Jaffe 1997
    1. Jaffe JH, Knapp CM, Ciraulo DA. Opiates: Clinical Aspects. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG editor(s). Substance Abuse: A Comprehensive Textbook. 3rd Edition. Baltimore: Williams & Wilkins, 1997.
Johnson 2003
    1. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug and Alcohol Dependence 2003;70(Suppl 2):S59‐S77. - PubMed
Kleber 1982
    1. Kleber HD, Riordan CE. The treatment of narcotic withdrawal: a historical review. Journal of Clinical Psychiatry 1982;43(6):30‐4. - PubMed
Kutz 2002
    1. Kutz I, Reznik V. Heroin detoxification with a single high dose of buprenorphine. Israel Journal of Psychiatry and Related Sciences 2002;39(2):113‐9. - PubMed
Lanier 2007
    1. Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE. Evaluation of a transdermal buprenorphine formulation in opioid detoxification. Addiction 2007;102(10):1648‐56. - PubMed
Lanier 2008
    1. Lanier RK, Umbricht A, Harrison JA, Nuwayser ES, Bigelow GE. Opioid detoxification via single 7‐day application of a buprenorphine transdermal patch: an open‐label evaluation. Psychopharmacology (Berlin) 2008;198(2):149‐58. - PMC - PubMed
Larance 2011
    1. Larance B, Degenhardt L, Lintzeris N, Bell J, Winstock A, Dietze P, et al. Post‐marketing surveillance of buprenorphine‐naloxone in Australia: diversion, injection and adherence with supervised dosing. Drug and Alcohol Dependence 2011;118(2‐3):265‐73. - PubMed
Lintzeris 2013
    1. Lintzeris N, Leung SY, Dunlop AJ, Larance B, White N, Rivas GR, et al. A randomised controlled trial of sublingual buprenorphine‐naloxone film versus tablets in the management of opioid dependence. Drug and Alcohol Dependence 2013;131(1‐2):119‐26. - PubMed
Lipton 1983
    1. Lipton D, Maranda M. Detoxification from heroin dependency: an overview of method and effectiveness. Advances in Alcohol and Substance Abuse 1983;2(1):31‐55.
Mark 2001
    1. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug and Alcohol Dependence 2001;61(2):195‐206. [MEDLINE: ] - PubMed
Mattick 1996
    1. Mattick RP, Hall W. Are detoxification programmes effective?. Lancet 1996;347(8994):97‐100. - PubMed
Mattick 2014
    1. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD002207.pub4] - DOI - PubMed
Minozzi 2014
    1. Minozzi S, Amato L, Davoli M. Detoxification treatments for opiate dependent adolescents. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD006749.pub3] - DOI - PMC - PubMed
Phillips 1986
    1. Phillips GT, Gossop M, Bradley B. The influence of psychological factors on the opiate withdrawal syndrome. British Journal of Psychiatry 1986;149:235‐8. [MEDLINE: ] - PubMed
Preston 1985
    1. Preston KL, Bigelow GE. Pharmacological advances in addiction treatment. International Journal of the Addictions 1985;20(6‐7):845‐67. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Satel 1993
    1. Satel SL, Kosten TR, Schuckit MA, Fischman MW. Should protracted withdrawal from drugs be included in DSM‐IV?. American Journal of Psychiatry 1993;150(5):695‐704. - PubMed
Sobel 2004
    1. Sobel B‐FX, Sigmon SC, Walsh SL, Johnson RE, Liebson IA, Nuwayser ES, et al. Open‐label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug and Alcohol Dependence 2004;73(1):11‐22. - PubMed
Strain 2004
    1. Strain EC, Moody DE, Stoller KB, Walsh SL, Bigelow GE. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug and Alcohol Dependence 2004;74:37‐43. - PubMed
Strang 1999
    1. Strang J, Griffiths P, Powis B, Gossop M. Heroin chasers and heroin injectors: differences observed in a community sample in London, UK. American Journal on Addictions 1999;8(2):148‐60. [MEDLINE: ] - PubMed
Tetrault 2009
    1. Tetrault JM, O'Connor PG. Management of opioid intoxication and withdrawal. In: Ries RK, Fiellin DA, Miller SC, Siatz R editor(s). Principles of Addiction Medicine. 4th Edition. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2009:589‐606.
Vaillant 1988
    1. Vaillant GE. What can long‐term follow‐up teach us about relapse and prevention of relapse in addiction?. British Journal of Addiction 1988;83(10):1147‐57. - PubMed
WHO 2009
    1. World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization, 2009. [ISBN 978 92 4 154754 3] - PubMed

References to other published versions of this review

Gowing 2004
    1. Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD002025.pub4] - DOI - PubMed
Gowing 2006
    1. Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD002025.pub4] - DOI - PubMed
Gowing 2009a
    1. Gowing L, Ali R, White JM, Mbewe D. Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD002025.pub4] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources